But Where Will We Stay? Traveling for Cancer Treatment

Every day more than 3,500 people in the United States are diagnosed with cancer. Many must travel to cancer centers specializing in their particular treatment needs. Combined with the millions who are already fighting this disease, it means tens of thousands of cancer patients every day throughout the United States are looking for a suitable place to stay.

Joe's House is a nonprofit organization providing a nation-wide online service that helps cancer patients and their families find lodging near treatment centers. Founded in 2003, Joe’s House was conceived after Ann Calahan’s first husband, Joe Warnecke, died of cancer. Joe battled the disease for six years. During those six years, Ann and Joe had difficulty finding appropriate accommodations in unfamiliar cities. Ann vowed to correct this problem.

Joe's House feels that patients deserve an accommodation expert to help them with their travel needs. They list various types of lodging throughout the United States. Details on each lodging facility are available with information on amenities, rates, and reservation methods and requirements.

For more information, contact Joe’s House (http://www.joeshouse.org) at [email protected] or call 877-JOESHOU (877-563-7468).

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap